GR851954B - - Google Patents

Info

Publication number
GR851954B
GR851954B GR851954A GR850101954A GR851954B GR 851954 B GR851954 B GR 851954B GR 851954 A GR851954 A GR 851954A GR 850101954 A GR850101954 A GR 850101954A GR 851954 B GR851954 B GR 851954B
Authority
GR
Greece
Application number
GR851954A
Other languages
Greek (el)
Inventor
Bruce Aungst
Roberto Cosmo Diluccio
Original Assignee
Du Pont
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont filed Critical Du Pont
Publication of GR851954B publication Critical patent/GR851954B/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GR851954A 1984-08-10 1985-08-08 GR851954B (oth)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63938584A 1984-08-10 1984-08-10
US06/741,762 US4626539A (en) 1984-08-10 1985-06-10 Trandermal delivery of opioids

Publications (1)

Publication Number Publication Date
GR851954B true GR851954B (oth) 1985-12-10

Family

ID=27093327

Family Applications (1)

Application Number Title Priority Date Filing Date
GR851954A GR851954B (oth) 1984-08-10 1985-08-08

Country Status (6)

Country Link
US (1) US4626539A (oth)
EP (1) EP0171742A3 (oth)
AU (1) AU574628B2 (oth)
GR (1) GR851954B (oth)
IL (1) IL76061A0 (oth)
NZ (1) NZ213067A (oth)

Families Citing this family (203)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4573995A (en) * 1984-10-09 1986-03-04 Alza Corporation Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine
US5135477A (en) * 1984-10-29 1992-08-04 Medtronic, Inc. Iontophoretic drug delivery
US4806341A (en) * 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US4992422A (en) * 1986-01-31 1991-02-12 Whitby Research, Inc. Compositions comprising 1-substituted azacycloalkanes
DE3779833T2 (de) * 1986-01-31 1993-02-04 Whitby Research Inc Zusammensetzungen enthaltend 1-substituierte azacycloalkane und deren verwendung.
US5204339A (en) * 1986-01-31 1993-04-20 Whitby Research, Inc. Penetration enhancers for transdermal delivery of systemic agents
US5256647A (en) * 1986-01-31 1993-10-26 Whitby Research, Inc. Compositions comprising 1-substituted azacycloalkanes
US4915685A (en) * 1986-03-19 1990-04-10 Petelenz Tomasz J Methods and apparatus for iontophoresis application of medicaments at a controlled ph through ion exchange
US5142044A (en) * 1986-04-23 1992-08-25 Whitby Research, Inc. Penetration enhancers for transdermal delivery of systemic agents
JPS62298530A (ja) * 1986-06-16 1987-12-25 Otsuka Pharmaceut Co Ltd 坐薬用医薬組成物
ZA875317B (en) * 1986-08-01 1988-01-25 Warner-Lambert Company Transdermal compositions
CA1308352C (en) * 1986-08-15 1992-10-06 James V. Peck Compositions comprising 1-oxohydrocarbyl-substituted azacyclohexanes
US5073544A (en) * 1986-08-15 1991-12-17 Whitby, Inc. Transdermal compositions of 1-oxohydrocarbyl-substituted azacyclohexanes
CA1319613C (en) * 1986-10-07 1993-06-29 Gevork Minaskanian Penetration enhancers for transdermal delivery of systemic agents
US5196410A (en) * 1986-10-31 1993-03-23 Pfizer Inc. Transdermal flux enhancing compositions
US4959365A (en) * 1986-10-31 1990-09-25 Pfizer Inc. Topical compositions of lipophilic pharmaceuticals agents
ES2042527T3 (es) * 1986-11-14 1993-12-16 Theratech Inc Un metodo para preparar una composicion farmaceutica aumentadora de la penetracion para la aplicacion topica.
US5006342A (en) * 1986-12-22 1991-04-09 Cygnus Corporation Resilient transdermal drug delivery device
US4906463A (en) * 1986-12-22 1990-03-06 Cygnus Research Corporation Transdermal drug-delivery composition
AU601528B2 (en) * 1986-12-22 1990-09-13 Ortho-Mcneil Pharmaceutical, Inc. Resilient transdermal drug-delivery device and compositions and devices employing fatty acid esters/ethers of alkanediols and percutaneous absorption enhancers
WO1988009676A1 (en) * 1987-06-01 1988-12-15 Warner-Lambert Company Fatty acids and their small chain esters as penetration enhancers in aqueous systems
US4879297A (en) * 1987-06-01 1989-11-07 Warner-Lambert Company Fatty acids and their small chain esters as penetration enhancers in aqueous systems
US4788064A (en) * 1987-07-31 1988-11-29 Warner-Lambert Company Transdermal delivery system
DE3729299A1 (de) * 1987-09-02 1989-03-23 Beiersdorf Ag Transdermales therapeutisches system
US4920101A (en) * 1987-09-30 1990-04-24 Nelson Research & Development Co. Compositions comprising 1-oxo- or thiohydrocarbyl substituted azacycloaklkanes
US4879275A (en) * 1987-09-30 1989-11-07 Nelson Research & Development Co. Penetration enhancers for transdermal delivery of systemic agent
US4994267A (en) * 1988-03-04 1991-02-19 Noven Pharmaceuticals, Inc. Transdermal acrylic multipolymer drug delivery system
CH679119A5 (oth) * 1988-05-13 1991-12-31 Sandoz Ag
EP0351897A3 (en) * 1988-06-17 1990-03-21 The Procter & Gamble Company Skin penetration system for salts of amine-functional drugs
US5236714A (en) * 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
CA2002299A1 (en) * 1988-11-10 1990-05-10 Eugene G. Drust Compositions for the transdermal delivery of buprenorphine salts
US5026556A (en) * 1988-11-10 1991-06-25 Norwich Eaton Pharmaceuticals, Inc. Compositions for the transdermal delivery of pharmaceutical actives
US4891377A (en) * 1988-12-02 1990-01-02 Board Of Regents Acting For And On Behalf Of University Of Michigan Transdermal delivery of the narcotic analgesics etorphine and analogs
DE69010076T2 (de) * 1989-05-25 1994-12-08 Takeda Chemical Industries Ltd Transdermales therapeutisches Mittel.
US4923875A (en) * 1989-07-10 1990-05-08 Baker Cummins Pharmaceuticals, Inc. Method for treatment of mast cell-mediated dermatologic disorders
US4956171A (en) * 1989-07-21 1990-09-11 Paco Pharmaceutical Services, Inc. Transdermal drug delivery using a dual permeation enhancer and method of performing the same
JP2610052B2 (ja) * 1989-11-07 1997-05-14 信越化学工業株式会社 外用ゲル基剤
AR246186A1 (es) * 1989-11-17 1994-07-29 Beta Pharm Co Procedimiento para fabricar un dispositivo para administrar estradiol por via transdermica.
US5096715A (en) * 1989-11-20 1992-03-17 Alko Ltd. Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist
DE3939376C1 (oth) * 1989-11-29 1991-05-08 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg, 5450 Neuwied, De
EP0432945A1 (en) * 1989-12-12 1991-06-19 Warner-Lambert Company A transdermal delivery system for treatment of cocaine and heroin addiction
ES2094809T3 (es) * 1990-03-30 1997-02-01 Yasunori Morimoto Composicion absorbible por via percutanea del clorhidrato de morfina.
NZ237489A (en) * 1990-04-18 1995-07-26 Alza Corp Device for electrotransport and reservoir therefor containing a fatty acid as permeation enhancing agent
US5149719A (en) * 1990-04-27 1992-09-22 Minnesota Mining And Manufacturing Company Composition for transdermal penetration of medicaments
US5069909A (en) * 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
US5057322A (en) * 1990-08-10 1991-10-15 Baker Cummins Dermatologicals, Inc. Method of treating mast cell disease
SE9003665D0 (sv) * 1990-11-16 1990-11-16 Kabivitrum Ab Morphine prodrugs
US5149538A (en) * 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
US5518734A (en) * 1991-09-25 1996-05-21 Beta Pharmaceuticals Co. Transdermal delivery system for estradiol and process for manufacturing said device
US5705185A (en) * 1991-09-25 1998-01-06 Beta Pharmaceuticals Co. Transdermal delivery of estradiol and process for manufacturing said device
US5229130A (en) * 1991-12-20 1993-07-20 Cygnus Therapeutics Systems Vegetable oil-based skin permeation enhancer compositions, and associated methods and systems
AU3595393A (en) * 1992-01-31 1993-09-01 Cygnus Therapeutic Systems Transdermal administration of buprenorphine in the form of ion pair complexes
JP2960832B2 (ja) * 1992-05-08 1999-10-12 ペルマテック テクノロジー アクチェンゲゼルシャフト エストラジオールの投与システム
US5900250A (en) * 1992-05-13 1999-05-04 Alza Corporation Monoglyceride/lactate ester permeation enhancer for oxybutnin
US5919478A (en) * 1993-06-25 1999-07-06 Alza Corporation Incorporating poly-N-vinyl amide in a transdermal system
ES2068154B1 (es) * 1993-07-13 1995-11-16 Cantabria Ind Farmaceutica Sa Nuevas formulaciones analgesicas con amplio intervalo de accion.
CA2165802A1 (en) * 1993-09-29 1995-04-06 Eun Soo Lee Monoglyceride/lactate ester permeation enhancer for oxybutynin
US5635204A (en) * 1994-03-04 1997-06-03 Montefiore Medical Center Method for transdermal induction of anesthesia, analgesia or sedation
US5962477A (en) * 1994-04-12 1999-10-05 Adolor Corporation Screening methods for cytokine inhibitors
US6190691B1 (en) 1994-04-12 2001-02-20 Adolor Corporation Methods for treating inflammatory conditions
US5552153A (en) * 1994-04-28 1996-09-03 Hoffman-La Roche Inc. Pharmaceutical composition for transdermal delivery
US5580574A (en) * 1994-04-28 1996-12-03 Hoffmann-La Roche Inc. Pharmaceutical composition for transdermal delivery
JP2819236B2 (ja) * 1994-05-06 1998-10-30 日東電工株式会社 経皮吸収製剤
DE4423850A1 (de) * 1994-07-07 1996-01-11 Labtec Gmbh Transdermales therapeutisches System zur Applikation von Naloxon
US5607940A (en) * 1994-07-18 1997-03-04 Stephen; Robert L. Morphine formulations for use by electromotive administration
US5589480A (en) * 1994-08-17 1996-12-31 Elkhoury; George F. Topical application of opioid analgesic drugs such as morphine
US5866143A (en) * 1995-03-24 1999-02-02 El Khoury And Stein, Ltd. Topical application of opioid drugs such as morphine for relief of itching and skin disease
US6573282B1 (en) 1995-09-12 2003-06-03 Adolor Corporation Peripherally active anti-hyperalgesic opiates
US5849761A (en) * 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
US6103258A (en) * 1996-04-12 2000-08-15 Simon; David Lew Salts and bases of the 17-(Cyclopropylmethyl)-4,5 alpha-epoxy-6-Methylenemorphinan-3,14 diol molecule for optimizing dopamine homeostasis during administration of opioid analgesics
US6271240B1 (en) 1996-05-06 2001-08-07 David Lew Simon Methods for improved regulation of endogenous dopamine in prolonged treatment of opioid addicted individuals
US20040024006A1 (en) * 1996-05-06 2004-02-05 Simon David Lew Opioid pharmaceutical compositions
US20030211157A1 (en) * 1996-05-06 2003-11-13 Simon David Lew Semi-sol delivery blend for water soluble molecules
JPH1036265A (ja) * 1996-07-19 1998-02-10 Nitto Denko Corp ブプレノルフィン経皮吸収製剤
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US5919473A (en) * 1997-05-12 1999-07-06 Elkhoury; George F. Methods and devices for delivering opioid analgesics to wounds via a subdermal implant
EP1009407B1 (en) 1997-09-04 2004-04-28 Novoneuron, Inc. Noribogaine in the treatment of pain and drug addiction
IT1294748B1 (it) * 1997-09-17 1999-04-12 Permatec Tech Ag Formulazione per un dispositivo transdermico
DE19834005A1 (de) * 1997-09-25 1999-04-01 Lohmann Therapie Syst Lts Säureadditionssalze von Morphin-Alkaloiden und deren Verwendung
DK1017696T3 (da) * 1997-09-25 2002-07-08 Lohmann Therapie Syst Lts Syreadditionssalte af morfin-alkaloider og deres anvendelse
US6143278A (en) * 1998-02-23 2000-11-07 Elkhoury; George F. Topical application of opioid analgesic drugs such as morphine
US6011022A (en) * 1998-03-03 2000-01-04 El Khoury; George F. Topical application of muscarinic analgesic drugs such as neostigmine
US5994330A (en) * 1998-11-09 1999-11-30 El Khoury; Georges F. Topical application of muscarinic agents such as neostigmine for treatment of acne and other inflammatory conditions
WO2000059483A2 (en) * 1999-04-01 2000-10-12 Alza Corporation Transdermal drug delivery devices comprising a polyurethane drug reservoir
DE19923551A1 (de) * 1999-05-21 2000-11-30 Lohmann Therapie Syst Lts Pharmazeutisches Präparat mit dem Wirkstoff Diamorphin und seine Verwendung in einem Verfahren zur Behandlung der Opiatsucht
GB9924797D0 (en) * 1999-10-20 1999-12-22 West Pharm Serv Drug Res Ltd Compound
DE19960154A1 (de) * 1999-12-14 2001-07-12 Lohmann Therapie Syst Lts Flache Arzneizubereitung zur transmucosalen Verabreichung von Oxycodon oder einem vergleichbaren Wirkstoff in der Mundhöhle, für die Anwendung in der Schmerztherapie und Suchttherapie
KR20030060771A (ko) 2000-04-28 2003-07-16 메모리얼 슬로안-케터링 캔서 센터 국소용 마취제/아편양약물 제제 및 이들의 용도
CA2417129A1 (en) 2000-08-11 2002-02-21 Temple University Of The Commonwealth System Of Higher Education Obesity controlling method
US7737109B2 (en) 2000-08-11 2010-06-15 Temple University Of The Commonwealth System Of Higher Education Obesity controlling method
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
US6569449B1 (en) 2000-11-13 2003-05-27 University Of Kentucky Research Foundation Transdermal delivery of opioid antagonist prodrugs
DE20220982U1 (de) 2001-03-16 2004-11-25 Alza Corp., Mountain View Transdermal-Pflaster zum Verabreichen von Fentanyl
ATE364380T1 (de) * 2001-03-16 2007-07-15 Alza Corp Transdermales pflaster zur verabreichung von fentanyl
US20050208117A1 (en) * 2001-03-16 2005-09-22 Venkatraman Subramanian S Transdermal administration of fentanyl and analogs thereof
US7820688B2 (en) * 2001-04-27 2010-10-26 Memorial Sloan-Kettering Cancer Center Topical anesthetic/opioid formulations and uses thereof
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
US6703398B2 (en) * 2001-11-26 2004-03-09 Oliver Yoa-Pu Hu Orally administered analgesic compositions containing nalbuphine
US20040033253A1 (en) * 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
HUE032656T2 (en) * 2002-04-05 2017-10-30 Euro Celtique Sa Pharmaceutical composition containing oxicodone and naloxone
TW200404581A (en) 2002-04-23 2004-04-01 Alza Corp Transdermal analgesic systems with reduced abuse potential
DE10237056A1 (de) * 2002-08-09 2004-03-04 Grünenthal GmbH Opiod-Rezeptor-Antagonisten in Transdermalen Systemen mit Buprenorphin
DK1530469T3 (da) * 2002-08-20 2009-05-04 Euro Celtique Sa Transdermal dosisform omfattende et aktivt middel og et salt og fri baseform af en antagonist
CN1703200B (zh) 2002-09-20 2012-02-29 奥尔制药公司 隔离亚单元和相关组合物及方法
US20040086551A1 (en) * 2002-10-30 2004-05-06 Miller Kenneth J. Fentanyl suspension-based silicone adhesive formulations and devices for transdermal delivery of fentanyl
US20040116470A1 (en) * 2002-12-16 2004-06-17 Nickel Alfred A. Novel use of ion channel active compound, meperidine, to mediate process of accelerated wound healing
KR101159828B1 (ko) 2003-04-30 2012-07-04 퍼듀 퍼머 엘피 활성제 구성요소 및 활성제 층의 원위부에 억제제 구성요소를 포함하는 내변조성 경피제형
US8790689B2 (en) 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
US20080020028A1 (en) * 2003-08-20 2008-01-24 Euro-Celtique S.A. Transdermal dosage form comprising an active agent and a salt and a free-base form of an adverse agent
DE10340428B4 (de) * 2003-09-02 2015-02-12 Acino Ag Opioides Analgetikum enthaltende transdermale Formulierung
CA2543610A1 (en) * 2003-10-30 2005-05-19 Alza Corporation Transdermal analgesic systems having reduced abuse potential
HRP20090363T1 (hr) 2004-02-23 2009-08-31 Euro-Celtique S.A. Transdermalni injektor opioida rezistentan na zlouporabu
US20050226929A1 (en) * 2004-04-12 2005-10-13 Jianbo Xie Controlled release opioid analgesic formulation
US8246977B2 (en) 2004-10-21 2012-08-21 Durect Corporation Transdermal delivery systems
US8252320B2 (en) 2004-10-21 2012-08-28 Durect Corporation Transdermal delivery system for sufentanil
US7910599B2 (en) * 2005-01-10 2011-03-22 John David Sinclair Method for treating eating disorders by selective extinction with transdermal naloxone
TW200640526A (en) * 2005-02-24 2006-12-01 Alza Corp Transdermal electrotransport drug delivery systems with reduced abuse potential
WO2006124585A2 (en) * 2005-05-13 2006-11-23 Alza Corporation Multilayer drug system for the delivery of galantamine
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
EP2308480B1 (en) 2005-09-23 2014-08-13 ALZA Corporation High Enhancer-Loading Polyacrylate Formulation for Transdermal Applications
US9056061B2 (en) * 2005-09-23 2015-06-16 Alza Corporation Transdermal nicotine salt delivery system
EP1937226A2 (en) * 2005-09-23 2008-07-02 Alza Corporation Transdermal galantamine delivery system
BRPI0616788A2 (pt) * 2005-09-30 2011-07-05 Tti Ellebeau Inc sistemas, dispositivos e métodos de transferência de fármaco de modo transdérmico, e métodos que empregam agonista opióide e/ou antagonista opóide
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
JP2009509659A (ja) * 2005-09-30 2009-03-12 Ｔｔｉ・エルビュー株式会社 生体界面への活性物質の送達のイオントフォレーシス装置及び方法
RU2008124805A (ru) * 2005-11-21 2009-12-27 Шеринг-Плоу Лтд. (CH) Фармацевтические композиции, содержащие бупренорфин
US8518926B2 (en) 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
WO2007121188A2 (en) * 2006-04-10 2007-10-25 Knopp Neurosciences, Inc. Compositions and methods of using r(+) pramipexole
DE102006019293A1 (de) * 2006-04-21 2007-10-25 LABTEC Gesellschaft für technologische Forschung und Entwicklung mbH Pflaster, enthaltend ein Fentanyl Analogum
US10960077B2 (en) * 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
ES2379117T3 (es) 2006-05-16 2012-04-20 Knopp Neurosciences, Inc. Composiciones de R(+) y S(-) pramipexol y métodos de utilización de las mismas
US20070278289A1 (en) * 2006-05-31 2007-12-06 Toshiba Tec Kabushiki Kaisha Payment adjusting apparatus and program therefor
SI2719378T1 (sl) 2006-06-19 2016-11-30 Alpharma Pharmaceuticals Llc Farmacevtski sestavki
US20080008745A1 (en) * 2006-06-21 2008-01-10 University Of Kentucky Research Foundation Transdermal delivery of naltrexone hydrochloride, naltrexol hydrochloride, and bis(hydroxy-methyl)propionyl-3-0 ester naltrexone using microneedles
US20080004671A1 (en) * 2006-06-28 2008-01-03 Alza Corporation Vagus nerve stimulation via orally delivered apparatus
US20080009782A1 (en) * 2006-06-28 2008-01-10 Alza Corporation Methods and Devices for Transdermal Electrotransport Delivery of Lofentanil and Carfentanil
EP2124556B1 (en) 2006-10-09 2014-09-03 Charleston Laboratories, Inc. Pharmaceutical compositions
US8524695B2 (en) 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
CA2681110A1 (en) 2007-03-14 2008-09-18 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazole diamines
US20080226702A1 (en) * 2007-03-16 2008-09-18 Endo Pharmaceuticals, Inc. Transdermal Delivery Form Disposal Systems and Methods
AU2008251467B2 (en) * 2007-05-11 2014-07-31 The Trustees Of The University Of Pennsylvania Methods of treatment of skin ulcers
US20090018154A1 (en) * 2007-05-17 2009-01-15 Endo Pharmaceuticals, Inc., A Corporation Of Delaware Opioid and methods of making and using the same
EP2152315B1 (en) 2007-05-25 2016-01-06 Indivior UK Limited Sustained delivery formulations of risperidone compounds
RU2499583C2 (ru) 2007-10-15 2013-11-27 Алза Корпорейшн Заместительное трансдермальное введение фентанила один раз в день
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
ES2620672T3 (es) 2008-01-09 2017-06-29 Charleston Laboratories, Inc. Comprimidos de doble capa que comprenden oxicodona y prometazina
EP2259780A2 (en) 2008-02-28 2010-12-15 Syntropharma Limited Pharmaceutical composition comprising naltrexone
KR20110071064A (ko) 2008-08-19 2011-06-28 크놉 뉴로사이언시스 인코포레이티드 (ｒ)-프라미펙솔을 사용하는 조성물 및 방법
RU2012101792A (ru) * 2009-06-19 2013-07-27 Нопп Ньюросайенсиз, Инк. Композиции и способы для лечения бокового амиотрофического склероза
WO2011006012A1 (en) 2009-07-08 2011-01-13 Charleston Laboratories Inc. Pharmaceutical compositions
JP5927506B2 (ja) 2010-04-13 2016-06-01 レルマダ セラピューティクス、インク． １−メチル−２’，６’−ピペコロキシリダイドの皮膚医薬組成物および使用方法
US8765737B1 (en) 2010-05-11 2014-07-01 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US9394294B2 (en) 2010-05-11 2016-07-19 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US8362007B1 (en) 2010-05-11 2013-01-29 Demerx, Inc. Substituted noribogaine
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
US8802832B2 (en) 2010-06-22 2014-08-12 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
US8637648B1 (en) 2010-06-22 2014-01-28 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
US9586954B2 (en) 2010-06-22 2017-03-07 Demerx, Inc. N-substituted noribogaine prodrugs
US8741891B1 (en) 2010-06-22 2014-06-03 Demerx, Inc. N-substituted noribogaine prodrugs
EP2595632A1 (en) 2010-07-23 2013-05-29 DemeRx, Inc. Noribogaine compositions
EP2481740B1 (en) 2011-01-26 2015-11-04 DemeRx, Inc. Methods and compositions for preparing noribogaine from voacangine
US9617274B1 (en) 2011-08-26 2017-04-11 Demerx, Inc. Synthetic noribogaine
JP2015509075A (ja) 2011-12-09 2015-03-26 デメレックス， インコーポレイテッド ノルイボガインの硫酸エステル
CA2855994A1 (en) 2011-12-09 2013-06-13 Demerx, Inc. Phosphate esters of noribogaine
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US8877921B2 (en) 2012-01-25 2014-11-04 Demerx, Inc. Synthetic voacangine
US9150584B2 (en) 2012-01-25 2015-10-06 Demerx, Inc. Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them
US9783535B2 (en) 2012-12-20 2017-10-10 Demerx, Inc. Substituted noribogaine
US9045481B2 (en) 2012-12-20 2015-06-02 Demerx, Inc. Substituted noribogaine
US8940728B2 (en) 2012-12-20 2015-01-27 Demerx, Inc. Substituted noribogaine
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
CA2942638C (en) 2013-03-15 2026-03-10 Demerx, Inc. Method for noribogaine treatment of addiction in patients on methadone
EP3838271B1 (en) 2013-07-12 2025-09-03 Areteia Therapeutics, Inc. Treating elevated levels of eosinophils and/or basophils
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
ES2813674T3 (es) 2013-08-13 2021-03-24 Knopp Biosciences Llc Composiciones y métodos para el tratamiento de trastornos de células plasmáticas y trastornos prolinfocíticos de células b
CA2921381A1 (en) 2013-08-13 2015-02-19 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
US9561232B2 (en) 2014-02-18 2017-02-07 Demerx, Inc. Low dose noribogaine for treating nicotine addiction and preventing relapse of nicotine use
US9345711B2 (en) 2014-02-18 2016-05-24 Demerx, Inc. Methods for acute and long-term treatment of drug addiction
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
US9561233B2 (en) 2014-03-13 2017-02-07 Demerx, Inc. Use of ibogaine for the treatment of pain
US9591978B2 (en) 2014-03-13 2017-03-14 Demerx, Inc. Methods and compositions for pre-screening patients for treatment with noribogaine
US20170217976A1 (en) * 2014-03-21 2017-08-03 Chironwells Gmbh 6-(amino acid)-morphinan derivatives in combination with permeation enhancers for use as an orally, rectally, transdermally or nasally administered medicament
CA2989550C (en) 2014-06-18 2023-08-08 Demerx, Inc. Halogenated indole and benzofuran derivatives of isoquinuclidene and processes for preparing them
US11135155B2 (en) 2014-07-08 2021-10-05 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US9549935B2 (en) 2014-07-14 2017-01-24 Demerx, Inc. Methods and compositions for treating migraines using noribogaine
US9592239B2 (en) 2014-09-12 2017-03-14 Demerx, Inc. Methods and compositions for ibogaine treatment of impulse control disorder, anxiety-related disorders, violence and/or anger, or regulating food intake
WO2016060122A1 (ja) * 2014-10-14 2016-04-21 久光製薬株式会社 貼付剤
AU2015353414B2 (en) 2014-11-26 2021-04-29 Demerx, Inc. Methods and compositions for potentiating the action of opioid analgesics using iboga alkaloids
US10016502B2 (en) * 2015-08-29 2018-07-10 Medrx Co., Ltd Patch preparation containing an acid scavenger
KR20180105115A (ko) * 2015-10-07 2018-09-27 코르메딕스, 인코포레이티드 타우로리딘의 피부-침투성 제제
US10493049B2 (en) 2016-02-10 2019-12-03 Niracle LLC Applicator-based transdermal drug delivery system for administration of drugs in combination with topical formulations
JP2019507181A (ja) 2016-03-04 2019-03-14 チャールストン ラボラトリーズ，インコーポレイテッド 医薬組成物
WO2018126133A1 (en) * 2016-12-29 2018-07-05 Cormedix Inc. Skin-penetrating formulation of taurolidine
EP3616699B1 (en) 2017-04-25 2021-06-09 Hisamitsu Pharmaceutical Co., Inc. Adhesive patch
KR102302577B1 (ko) 2017-04-25 2021-09-14 히사미쓰 세이야꾸 가부시키가이샤 첩부제
WO2019064026A1 (en) 2017-09-29 2019-04-04 Orexo Ab NEW PHARMACEUTICAL COMPOSITIONS
EP3743072B1 (en) * 2018-01-22 2023-10-25 Foresee Pharmaceuticals Co., Ltd. Pharmaceutical composition for sustained release delivery of buprenorphine
WO2019167070A1 (en) 2018-02-27 2019-09-06 Akshay Sanghavi Topical copper tripeptide composition and process of preparation.
GB201904767D0 (en) 2019-04-04 2019-05-22 Orexo Ab New pharmaceutical compositions
US20220378729A1 (en) 2019-11-06 2022-12-01 Smartech Topical, Inc. Topical formulations of cyclooxygenase inhibitors and their use
US12364692B2 (en) 2020-02-14 2025-07-22 Teikoku Pharma Usa, Inc. Topical naloxone compositions and methods for using the same
EP4308088B1 (en) 2021-11-08 2025-03-12 Weiyong Li Transdermal drug delivery system for delivering a drug to a patient

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3275510A (en) * 1966-09-27 Topical antitussive preparations
US3888995A (en) * 1968-07-19 1975-06-10 Syntex Corp Fatty alcohol-propylene glycol vehicle
US3592930A (en) * 1968-07-19 1971-07-13 Syntex Corp Moisture-deterioratable topical medicaments,particularly anti-inflammatory steroids,in a substantially non-aqueous fatty alcohol-propylene glycol vehicle
US3924004A (en) * 1971-11-24 1975-12-02 Syntex Corp Fatty alcohol-propylene carbonate-glycol solvent cream vehicle
US3867528A (en) * 1973-10-11 1975-02-18 American Cyanamid Co Steroidal topical cream base
AU513753B2 (en) * 1974-07-08 1980-12-18 Johnson & Johnson Antimicrobial composition
US4405616A (en) * 1975-06-19 1983-09-20 Nelson Research & Development Company Penetration enhancers for transdermal drug delivery of systemic agents
US4299826A (en) * 1979-10-12 1981-11-10 The Procter & Gamble Company Anti-acne composition
AU8524782A (en) * 1981-04-28 1982-11-24 Hussain, A.A. Novel method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4416886A (en) * 1981-07-29 1983-11-22 Dermall Limited Method of treating pruritis and composition therefor
EP0095813A3 (en) * 1982-06-01 1985-05-08 THE PROCTER & GAMBLE COMPANY Penetrating topical pharmaceutical compositions containing 9-(2-hydroxyethoxymethyl) guanine
AU8952282A (en) * 1982-08-25 1984-03-29 Joel E. Bernstein Method of treating pruritis and composition therefor
DE3233638A1 (de) * 1982-09-10 1984-03-15 Thilo & Co Gmbh Dr Dermatologische zubereitung
GB8302683D0 (en) * 1983-02-01 1983-03-02 Unilever Plc Skin treatment composition
US4573995A (en) * 1984-10-09 1986-03-04 Alza Corporation Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine

Also Published As

Publication number Publication date
EP0171742A3 (en) 1987-12-16
US4626539A (en) 1986-12-02
IL76061A0 (en) 1985-12-31
AU4590585A (en) 1986-02-13
AU574628B2 (en) 1988-07-07
NZ213067A (en) 1988-05-30
EP0171742A2 (en) 1986-02-19

Similar Documents

Publication Publication Date Title
AT379850B (oth)
FR2571304B1 (oth)
GR851991B (oth)
AU2557584A (oth)
AU2219783A (oth)
BG45273A1 (oth)
BE900712A (oth)
BG38294A1 (oth)
BG39778A1 (oth)
BG44718A1 (oth)
BG44723A1 (oth)
BG44737A1 (oth)
BG44749A1 (oth)
BG44806A1 (oth)
BG44829A1 (oth)
BG44830A1 (oth)
BG44848A1 (oth)
BG44917A1 (oth)
BG44933A1 (oth)
BG44935A1 (oth)
BG45025A1 (oth)
BG45054A1 (oth)
BG45060A1 (oth)
BG45079A1 (oth)
BG45080A1 (oth)